Zymenex A/S clinical trials
Acquired by Chiesi Farmaceutici S.p.A.
The registry lists 8 studies whose lead sponsor is Zymenex A/S. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 20, 2020.
Status
- Completed
- 7
- Status unknown
- 1
Registry sponsor names on this page
- Zymenex A/S8 studies
Something wrong with this grouping? Tell us on the Chiesi Farmaceutici S.p.A. page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Chiesi Farmaceutici S.p.A. studies →
- Evaluation of Long-term Efficacy of Treatment With LamazymCompletedNCT02478840Phase 3
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- The Natural History of Alpha-MannosidosisCompletedNCT00498420
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisCompletedNCT01268358Phase 1
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisCompletedNCT01681953Phase 3
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- Porphozym in the Treatment of Acute Attacks in AIPCompletedNCT00418795Phase 2/3
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- The Natural History of Infantile Globoid Cell LeukodystrophyCompletedNCT00983879
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-MannosidosisCompletedNCT01681940Phase 2
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group
- Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosisStatus unknownNCT01285700Phase 2
Sponsor listed in the registry: Zymenex A/S · Zymenex A/S — acquired company within the Chiesi Farmaceutici S.p.A. group